Wu 2015.

Methods	Randomised clinical trial, China Parallel group design
Participants	92 participants diagnosed with chronic hepatitis B (not reported any diagnosis criteria or inclusion criteria). Male:female: 55:37 Mean age: experimental group: 44.1 years, control group: 44.5 years. Exclusion criteria: not reported
Interventions	Experimental intervention: Xiao Chai Hu Tang formula (detailed constitution of formula not reported), 100 mL twice a day, water decoction, 24 weeks (n = 46) Control intervention: no intervention (n = 46) Co‐intervention: lamivudine 100 mg once daily, 24 weeks
Outcomes	Improvement of liver function biomarkers (ALT, AST, ALB, TBIL level in serum) and portal vein dynamics (comparison of portal vein width and portal vein velocity)
Notes	Study dates: November 2013 to December 2014 Authors used intention‐to‐treat We contacted the authors by telephone on 23 March 2018, but authors did not want to provide any information. No further contact details.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Except the equally implemented co‐interventions, the experimental group received Xiao Chai Hu Tang formula and the control group received no nothing. This could have unblinded the trial.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	The number of participants included in the analysis was equal to the number of participants randomised.
Selective reporting (reporting bias)	High risk	This study did not report any of our predefined primary outcomes, and we could not find the study protocol.
Other bias	Low risk	The study appeared free of other factors that could have put it at risk of bias.